PXL01 program entering Phase III clinical trial

A biotech with global reach

Therapeutic peptides for bioactive wound care

Two first-in-category product candidates

New medical concept with extraordinary safety

Strategic partnerships in EU, Asia and USA

Innovative treatments for local administration

Press releases

July 14, 2020Promore Pharma is Granted a Patent for ropocamptide in the US
May 28, 2020Promore Pharma Appoints Erik Magnusson as Chief Financial Officer
May 26, 2020Report from the Annual General Meeting of Promore Pharma AB held on 26 May 2020
May 26, 2020Promore Pharma AB (publ) Interim report January – March 2020

More Press Releases

INTERIM REPORT JANUARY – MARCH 2020

Promore Pharma AB (publ) published its interim report for the first quarter 2020 at 13.00 CET on 26 May 2020.

Read the report

Calendar

August 25, 2020Interim report January – June 2020
November 24, 2020Interim report January – September 2020

More Events

Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides for the bioactive wound care market. The company’s aim is to develop two first-in-category products for indications with very few efficacious prescription pharmaceuticals, addressing high unmet medical need.

Vision

The vision of Promore Pharma is to solve the global medical problems of scarring, adhesions and chronic wounds.

Market

Within the global wound care market Promore Pharma’s product candidates are intended for the bioactive wound care segment. The bioactive wound care segment constitutes the fastest growing segment within the overall wound care market with a projected annual growth rate from 2015-2020 of 14 percent and is expected to reach USD 7.3 billion in 2020.